English | 简体中文 | 繁體中文 | 한국어 | 日本語
  Press Releases
Tuesday, November 30, 2021
エーザイとFCNT、認知症との共生と予防に向けた業務提携契約を締結
エーザイ、第75回米国てんかん学会年次総会にてペランパネルおよびE2730に関する最新データを発表
Eisai and FCNT Enter Into Business Alliance Aiming to Support People Living with Dementia and to Prevent Dementia
Eisai to Present Latest Data on Perampanel and E2730 at the 75th American Epilepsy Society Annual Meeting
Monday, November 29, 2021
エーザイとMSD、「レンビマ(R)」と「キイトルーダ(R)」の併用療法による子宮内膜がんに係る承認を欧州委員会より取得
European Commission Approves LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) for Patients With Certain Types of Endometrial Carcinoma
European Commission Approves LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) as First-Line Treatment for Adult Patients With Advanced Renal Cell Carcinoma
Friday, November 19, 2021
エーザイ、社会的責任投資指数「Dow Jones Sustainability Asia Pacific Index」に8回目の選定
エーザイ、IR優良企業賞2021において「“共感!”IR賞」を受賞
Thursday, November 18, 2021
Eisai Receives the 'Most Liked!' IR Award at The 2021 IR Award

Copyright © 2021 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Cookies Policy | Privacy Policy | Disclaimer | Terms of Use | RSS
US: +1 214 890 4418 | Beijing: +86 400 879 3881 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575